Nuvectra to Present at the 28th Annual Piper Jaffray Healthcare Conference
November 21 2016 - 8:00AM
Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical
device company, announced today that Scott Drees, Chief Executive
Officer, and Walter Berger, Chief Financial Officer, are scheduled
to present at the 28th Annual Piper Jaffray Healthcare Conference
in New York, NY. Management will also be available for one-on-one
meetings at the conference.
Event: |
|
28th Annual
Piper Jaffray Healthcare Conference |
Format: |
|
Presentation and One-on-One Meetings |
Date: |
|
Wednesday,
November 30th, 2016 |
Time: |
|
3:20 pm
ET |
|
|
|
A webcast of the Company’s presentation will be available by
visiting the investor relations section of Nuvectra’s website at
www.nuvectramed.com. A webcast replay of the presentation will be
available for 90 days.
About Nuvectra Corporation
Nuvectra™ is a neurostimulation company
committed to helping physicians improve the lives of people with
chronic neurological conditions. The Algovita® Spinal Cord
Stimulation (SCS) System is our first commercial offering and is CE
marked and FDA approved for the treatment of chronic pain of the
trunk and/or limbs. Our innovative technology platform also has
capabilities under development to support other neurological
indications such as sacral nerve stimulation (SNS), and deep brain
stimulation (DBS). In addition, our NeuroNexus subsidiary designs,
manufactures and markets leading-edge neural-interface technologies
for the neuroscience clinical research market. Visit the Nuvectra
website at www.nuvectramed.com.
Company Contacts:
Nuvectra Corporation
Walter Berger, Chief Financial Officer
(214) 474-3102
wberger@nuvectramed.com
Jennifer Armstrong, Media Relations
(214) 474-3110
jarmstrong@nuvectramed.com
Investor Contacts:
The Ruth Group
Nick Laudico
(646) 536-7030
nlaudico@theruthgroup.com
Zack Kubow
(646) 536-7020
zkubow@theruthgroup.com
Nuvectra (NASDAQ:NVTR)
Historical Stock Chart
From Sep 2024 to Oct 2024
Nuvectra (NASDAQ:NVTR)
Historical Stock Chart
From Oct 2023 to Oct 2024